|
🐜
|
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
33 auth.
C. Tam,
Stephen Samuel Opat,
S. D’Sa,
W. Jurczak,
Hui-Peng Lee,
G. Cull,
R. Owen,
P. Marlton,
B. Wahlin,
R. G. Sanz,
H. McCarthy,
S. Mulligan,
A. Tedeschi,
J. Castillo,
J. Czyż,
...
C. Fernández de Larrea,
D. Belada,
E. Libby,
J. Matous,
M. Motta,
T. Siddiqi,
M. Tani,
M. Trněný,
M. Minnema,
C. Buske,
V. Leblond,
J. Trotman,
W. Chan,
J. Schneider,
S. Ro,
A. Cohen,
Jane E. Huang,
M. Dimopoulos
|
8 |
2020 |
8
🐜
|
|
🐜
|
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
21 auth.
C. Tam,
J. Trotman,
Stephen Samuel Opat,
J. Burger,
G. Cull,
D. Gottlieb,
R. Harrup,
P. Johnston,
P. Marlton,
J. Muñoz,
...
J. Seymour,
D. Simpson,
A. Tedeschi,
R. Elstrom,
Yiling Yu,
Zhiyu Tang,
Lynn Han,
Jane E. Huang,
W. Novotny,
Lai Wang,
A. Roberts
|
8 |
2019 |
8
🐜
|
|
🐜
|
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
19 auth.
J. Bromberg,
S. Issa,
K. Bakunina,
M. Minnema,
T. Seute,
M. Durian,
G. Cull,
H. Schouten,
W. Stevens,
J. Zijlstra,
...
J. Baars,
M. Nijland,
K. Mason,
A. Beeker,
M. J. van den Bent,
M. Beijert,
M. Gonzales,
D. de Jong,
J. Doorduijn
|
7 |
2019 |
7
🐜
|
|
🐜
|
Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review
8 auth.
G. Kennedy,
Siok-Keen Tey,
R. Cobcroft,
P. Marlton,
G. Cull,
K. Grimmett,
...
D. Thomson,
D. Gill
|
6 |
2002 |
6
🐜
|
|
🐜
|
When the safety net of treatment has been removed: patients' unmet needs at the completion of treatment for haematological malignancies.
8 auth.
Elizabeth A. Lobb,
Elizabeth A. Lobb,
David Joske,
Phyllis Butow,
Linda J. Kristjanson,
P. Cannell,
...
G. Cull,
B. Augustson
|
6 |
2009 |
6
🐜
|
|
🐜
|
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
18 auth.
J. Trotman,
Stephen Samuel Opat,
D. Gottlieb,
D. Simpson,
P. Marlton,
G. Cull,
J. Muñoz,
A. Tedeschi,
A. Roberts,
J. Seymour,
...
S. Atwal,
Yiling Yu,
W. Novotny,
E. Holmgren,
Z. Tan,
J. Hilger,
Jane E. Huang,
C. Tam
|
6 |
2020 |
6
🐜
|
|
🐜
|
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
14 auth.
C. Tam,
Stephen Samuel Opat,
D. Simpson,
G. Cull,
J. Muñoz,
T. Phillips,
W. Kim,
S. Rule,
S. Atwal,
R. Wei,
...
W. Novotny,
Jane E. Huang,
Michael L. Wang,
J. Trotman
|
6 |
2021 |
6
🐜
|
|
🐜
|
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
34 auth.
M. Dimopoulos,
R. G. Sanz,
Hui-Peng Lee,
M. Trněný,
M. Varettoni,
Stephen Samuel Opat,
S. D’Sa,
R. Owen,
G. Cull,
S. Mulligan,
J. Czyż,
J. Castillo,
M. Motta,
T. Siddiqi,
M. Gironella Mesa,
...
Miquel Granell Gorrochategui,
D. Talaulikar,
P. Zinzani,
E. Askari,
S. Grosicki,
A. Oriol,
S. Rule,
J. Kłoczko,
A. Tedeschi,
C. Buske,
V. Leblond,
J. Trotman,
W. Chan,
Jan Michel,
J. Schneider,
Z. Tan,
A. Cohen,
Jane E. Huang,
C. Tam
|
6 |
2020 |
6
🐜
|
|
🐜
|
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
29 auth.
C. Tam,
M. Dimopoulos,
R. García-Sanz,
J. Trotman,
Stephen Samuel Opat,
A. Roberts,
R. Owen,
Yuqin Song,
Wei Xu,
Jun Zhu,
Jianyong Li,
L. Qiu,
S. D’Sa,
W. Jurczak,
G. Cull,
...
P. Marlton,
D. Gottlieb,
J. Muñoz,
T. Phillips,
C. Du,
M. Ji,
Lei Zhou,
Haiyi Guo,
Hongjie Zhu,
W. Chan,
A. Cohen,
W. Novotny,
Jane E. Huang,
A. Tedeschi
|
6 |
2021 |
6
🐜
|
|
🐜
|
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
24 auth.
M. Hertzberg,
M. Gandhi,
J. Trotman,
B. Butcher,
J. Taper,
A. Johnston,
D. Gill,
Shir-Jing Ho,
G. Cull,
K. Fay,
...
G. Chong,
A. Grigg,
I. Lewis,
S. Milliken,
William E. P. Renwick,
U. Hahn,
R. Filshie,
G. Kannourakis,
A. Watson,
P. Warburton,
A. Wirth,
J. Seymour,
M. Hofman,
R. Hicks
|
5 |
2017 |
5
🐜
|
